Cerevance Revenue and Competitors

Boston, MA USA

Location

$91.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cerevance's estimated annual revenue is currently $6.1M per year.(i)
  • Cerevance's estimated revenue per employee is $100,500
  • Cerevance's total funding is $91.5M.

Employee Data

  • Cerevance has 61 Employees.(i)
  • Cerevance grew their employee count by 9% last year.

Cerevance's People

NameTitleEmail/Phone
1
Co-founder and Board ChairReveal Email/Phone
2
CEOReveal Email/Phone
3
CSO & Co-FounderReveal Email/Phone
4
CEOReveal Email/Phone
5
ControllerReveal Email/Phone
6
SVP, Clinical and Translational MedicineReveal Email/Phone
7
VP Drug DiscoveryReveal Email/Phone
8
VP NeuroscienceReveal Email/Phone
9
Head Molecular Biology and Cell EngineeringReveal Email/Phone
10
Head FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Cerevance?

Cerevance

keywords:N/A

$91.5M

Total Funding

61

Number of Employees

$6.1M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cerevance News

2022-04-17 - Leadership transition at Cerevance

Brad Margus will transition from CEO of Cerevance to executive chairman of the board at the end of April. Cerevance was launched by Japan's...

2022-04-13 - Cerevance Announces Leadership Transition to Implement ...

BOSTON, April 19, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central...

2022-03-22 - With Positive Phase II Results, Cerevance Proves Concept in ...

Cerevance is focused on brain and central nervous system (CNS) disease treatments. Most of the company's drug discovery comes from the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.4M613%$62.6M
#2
$8.2M610%N/A
#3
$11.5M61-6%N/A
#4
$15.9M612%N/A
#5
$11.7M61-54%$277.7M